Previous Section Index Home Page

6 Oct 2008 : Column 448W—continued


6 Oct 2008 : Column 449W

6 Oct 2008 : Column 450W

6 Oct 2008 : Column 451W

6 Oct 2008 : Column 452W
Topic Work programme Published/ongoing Date of marketing authorisation( 1) Referral date( 2) Date of final NICE guidance Start of NICE appraisal( 3)

Xolair (omalizumab) for uncontrolled asthma

8

Published

October 2005

April 2003

November 2007

November 2006

Remicade (infliximab) for psoriasis

8

Published

September 2005

April 2003

January 2008

March 2007

Natrecor (nesiritide), Heart failure (acute decompensated)

9

Ongoing

n/a

October 2003

n/a

October 2003

Erbitux (cetuximab), Head and neck cancer

10

Published

n/a

June 2004

June 2008

June 2006

Iressa (gefitinib), lung cancer (non-small cell)

10

Ongoing

n/a

June 2004

n/a

January 2009

Tysabri (natalizumab) for the treatment of multiple sclerosis

10

Published

June 2006

June 2004

August 2007

September 2006

Alimta (pemetrexed) for mesothelioma

10

Published

September 2004

June 2004

January 2008

April 2005

Erbitux (cetuximab) for head and neck cancer

10

Published

March 2006

June 2004

June 2008

June 2006

Campto (irinotecan), colon cancer (adjuvant)

10

Ongoing

n/a

June 2004

n/a

n/a

Mabthera (rituximab) for untreated stage III or IV follicular lymphoma

11

Published

August 2004

April 2005

September 2006

April 2007

Taxol (paclitaxel) for early node-positive breast cancer

11

Published

March 2005

April 2005

September 2006

November 2005

Taxotere (docetaxel) for early node-positive breast cancer

11

Published

March 2006

April 2005

September 2006

November 2005

Gemzar (gemcitabine) for metastatic breast cancer

11

Published

September 2004

April 2005

January 2007

February 2006

Fludara (fludarabine) for chronic lymphocytic leukaemia

11

Published

February 2003

April 2005

February 2007

February 2006

Alimta (pemetrexed) for the treatment of non-small cell lung cancer

11

Published

n/a

April 2005

August 2007

April 2006

Tarceva (erlotinib), lung cancer (non-small cell)

11

Ongoing

September 2005

April 2005

n/a

March 2009

Idraparinux sodium, atrial fibrillation

12

Ongoing

n/a

July 2006

n/a

July 2006

Arava (leflunomide), psoriatic arthritis (moderate to severe)

12

Ongoing

June 2004

July 2006

n/a

July 2006

Idraparinux sodium, venous thromboembolism (recurrent)

12

Ongoing

n/a

July 2006

n/a

July 2006

Herceptin (trastuzumab) for early-stage HER2-positive breast cancer

12

Published

May 2006

July 2005

August 2006

December 2005

Alteplase (Actilyse) for the treatment of acute ischaemic stroke

12

Published

June 2002

July 2006

June 2007

September 2006

Champix (varenicline) for smoking cessation

12

Published

September 2006

July 2006

July 2007

November 2006

Humira (adalimumab) for the treatment of psoriatic arthritis

12

Published

August 2005

July 2005

August 2007

September 2006

MabThera (rituximab) for the treatment of rheumatoid arthritis

12

Published

July 2006

July 2005

August 2007

September 2006

Velcade (bortezomib) for multiple myeloma

12

Published

April 2004

July 2005

October 2007

December 2005

Orencia (abatacept) for rheumatoid arthritis

12

Published

May 2007

July 2006

April 2008

October 2006

Tyverb (lapatinib), breast cancer (advanced or metastatic)

13

Ongoing

June 2008

December 2006

n/a

February 2007

Cimzia (certolizumab), rheumatoid arthritis

13

Ongoing

n/a

December 2006

n/a

December 2006

Remicade (infliximab), ulcerative colitis (acute exacerbations)

13

Ongoing

February 2006

December 2006

n/a

March 2007

Remicade (infliximab) for ulcerative colitis

13

Published

February 2006

December 2006

April 2008

March 2007

Acomplia (rimonabant) for obesity

13

Published

June 2006

December 2006

June 2008

June 2007

Baraclude (entecavir), Hepatitis B

14

Ongoing

June 2006

June 2007

August 2008

September 2007

Sebivo (telbivudine), Hepatitis B

14

Ongoing

April 2007

June 2007

August 2008

September 2007

Adenuric (febuxostat), hyperuricaemia

14

Ongoing

April 2008

June 2007

n/a

August 2007

Humira (adalimumab) for the chronic psoriasis

14

Published

December 2007

June 2007

June 2008

July 2007

Ixabepilone, breast cancer (locally advanced or metastatic)

15

Ongoing

n/a

December 2007

n/a

July 2008

Erbitux (cetuximab), colorectal cancer (first line)

15

Ongoing

July 2008

December 2007

n/a

January 2008

Erbitux (cetuximab), lung cancer (non-small cell)

15

Ongoing

n/a

December 2007

n/a

October 2008

Revlimid (lenalidomide), multiple myeloma

15

Ongoing

June 2007

December 2007

n/a

April 2008

Xeloda (capectitabine), pancreatic cancer

15

Ongoing

n/a

December 2007

n/a

June 2009

Pradaxa (dabigatran), venous thromboembolism

15

Ongoing

March 2008

December 2007

n/a

January 2008

Erbitux (cetuximab), head and neck cancer (squamous cell carcinoma)

16

Ongoing

March 2006

March 2008

n/a

March 2008

Effient (prasugrel), acute coronary artery syndrome

17

Ongoing

n/a

June 2008

n/a

November 2008

Viread (tenofovir disoproxil fumarate), Hepatitis B

17

Ongoing

April 2008

June 2008

n/a

August 2008

Nexavar (sorafenib), hepatocellular carcinoma (advanced and metastatic)

17

Ongoing

October 2007

June 2008

n/a

August 2008

Orencia (abatacept), juvenile idiopathic arthritis

17

Ongoing

May 2007

June 2008

n/a

January 2009

Humira (adalimumab), juvenile idiopathic arthritis

17

Ongoing

n/a

June 2008

n/a

September 2008

Sprycel (dasatinib), leukaemia (acute lymphoblastic)

17

Ongoing

November 2006

June 2008

n/a

July 2008

Temodal (temoazolomide), melanoma (advanced and metastatic

17

Ongoing

June 2005

June 2008

n/a

March 2009

Mifamurtide, Osteosarcoma

17

Ongoing

n/a

June 2008

n/a

August 2008

Romiplostim, thrombocytompenic pupura

17

Ongoing

n/a

June 2008

n/a

August 2008

Promacta (eltrombopag), thrombocytopenic purpura

17

Ongoing

n/a

June 2008

n/a

March 2009

Xarelto (rivaroxaban), venous thromboembolism

17

Ongoing

n/a

June 2008

n/a

August 2008

Azacitidine, acute myelomonocytic leukaemia and acute myeloid leukaemia

18

Ongoing

n/a

July 2008

n/a

January 2009

Xeloda (capecitabine), advanced gastric cancer

18

Ongoing

January 2008

July 2008

n/a

December 2008

Methylnaltrexone, opioid-induced constipation in patients receiving palliative care

18

Ongoing

n/a

July 2008

n/a

February 2009

Datiros (alitretinoin), severe chronic hand eczema

18

Ongoing

n/a

July 2008

n/a

October 2008

Alimta (pemetrexed), locally advanced or metastatic non-small cell lung cancer

18

Ongoing

April 2008

July 2008

n/a

June 2009

Mabthera (rituximab), relapsed treatment of chronic lymphocytic leukaemia

18

Ongoing

n/a

July 2008

n/a

September 2009

Mabthera (rituximab), chronic lymphocytic leukaemia.

18

Ongoing

n/a

July 2008

n/a

September 2008

Sutent (sunitinib), gastrointestinal stromal tumours

18

Ongoing

July 2006

July 2008

n/a

August 2008

Actemra (tocilizumab), rheumatoid arthritis

18

Ongoing

n/a

July 2008

n/a

November 2008

Hycamtin (topotecan), carcinoma of the cervix

18

Ongoing

n/a

July 2008

n/a

December 2008

Yondelis (trabectedin), advanced metastatic soft tissue sarcoma

18

Ongoing

September 2007

July 2008

n/a

September 2008

Ustekinumab, moderate to severe psoriasis

18

Ongoing

n/a

July 2008

n/a

November 2008

(1) Date of marketing authorisation by European Medicines Agency (EMEA).
(2) Topics before the 13 work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to NICE as a Multiple Technology Appraisal.
(3) The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.


Next Section Index Home Page